How do I buy Dr. Reddy`s Laboratories Ltd. - ADR (RDY) stock?

Buying Dr. Reddy`s Laboratories Ltd. - ADR (RDY) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "RDY", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy RDY by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for RDY on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Dr. Reddy`s Laboratories Ltd. - ADR from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Dr. Reddy`s Laboratories Ltd. - ADR (RDY) pay dividends?

Yes, Dr. Reddy`s Laboratories Ltd. - ADR regularly pays dividends to shareholders. Currently, the estimated dividend yield for RDY is around 1.05% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Is buying RDY on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy RDY?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if RDY is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Dr. Reddy`s Laboratories Ltd. - ADR (RDY) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

Reuters

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

NeutralRDYSeptember 18, 2026

ReutersNeutral

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

RDY

Business Wire

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

NeutralRDYAugust 20, 2026

Business WireNeutral

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

RDY

Business Wire

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

NeutralRDYAugust 20, 2026

Business WireNeutral

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

RDY

Business Wire

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

NeutralRDYAugust 19, 2026

Business WireNeutral

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

RDY

Business Wire

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NeutralRDYAugust 14, 2026

Business WireNeutral

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

RDY

Business Wire

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

NeutralRDYAugust 4, 2026

Business WireNeutral

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

RDY

Business Wire

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

NeutralRDYJuly 28, 2026

Business WireNeutral

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

RDY

CNBC International TV

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

NeutralRDYJuly 24, 2026

CNBC International TVNeutral

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

RDY

CNBC

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

NeutralRDYJuly 24, 2026

CNBCNeutral

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

RDY

Zacks Investment Research

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

NeutralRDYJuly 23, 2026

Zacks Investment ResearchNeutral

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

RDY

About Dr. Reddy`s Laboratories Ltd. - ADR

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees27,527

CEOMr. Erez Israeli M.B.A.

IPO DateApr 11, 2001

HeadquartersHyderabad, India

Key Executives

Name	Title	Year Born
Mr. Gunupati Venkateswara Prasad B.E.	Co-Chairman, MD & Member of Management Council	1960
Mr. Kallam Satish Reddy B.Tech., M.S.	Chairman of the Board & Member of the Management Council	1967
Mr. Erez Israeli M.B.A.	CEO & Member of the Management Council	1968
Mr. Mannam Venkatanarasimham	CFO & Member of the Management Council	1970
Mr. Krishna K. Venkatesh B.Pharma M.S.	Global Head of IPDO, Integrated Product Development & Member of the Management Council	1973
Mr. Deepak Sapra M.B.A.	CEO ? API and Services & Member of Management Council	1975
Mr. Motupalli Venkata Ramana M.B.A.	CEO of Global Generics & Member of Management Council	1969
Mr. Sanjay Sharma B.Tech.	Executive VP, COO & Member of Management Council	1968
Mr. Patrick Aghanian B.A., M.B.A.	Head of Consumer Health Organization & Member of Management Council	1965
Mr. Bhethanabottla S. Phanimitra	Chief Digital & Information Officer and Member of the Management Council	1980

Fundamentals

Valuation

Market cap$10.20B

Price-to-sales ratio2.74

Price-to-book value2.44

Price-earnings ratio23.00

Return on Equity12.00%

Return on Sales18.00%

Return on Assets8.00%

PEG ratio1.65

Earnings Per Share

Earnings Per Share$0.57

Income Statement

Average volume2,747,788

EBITDA$885.79M

1 year high (52w)$15.67

1 year low (52w)$11.36

Dividend

Ex dividend date24 Jul 2026

Dividend amount$0.09

Dividend yield1.05%

Last payment dateN/A

Dividend yield (TTM)0.64%

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsBuy5 Indicators

Moving AveragesBuy12 Indicators

What the experts say

0 Wall Street Analyst Ratings

N/A

0% Buy

0% Hold

0% Sell

Target price

$0.00

Est return

0.00%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021									-0.1	-7.4	-1.7	+6.3
2022	-11.9	-6.6	+5.9	-3.8	+3.7	+0.3	-7.8	+1.6	-1.3	+0.3	+1.0	-7.8
2023	+4.0	-3.1	+7.0	+5.4	-9.4	+13.1	+9.8	-1.9	-1.8	-2.0	+6.7	+0.0
2024	+1.6	+6.1	-1.9	-0.7	-7.2	+9.7	+7.8	+1.1	-2.0	-7.2	-4.8	+10.4
2025	-11.8	-6.1	+3.4	+5.8	+6.4	+2.0	-4.8	+1.9	-1.0	-6.4	+4.8	+0.7
2026	-3.2	+5.7	-3.7	+1.3	-0.7	+9.3	-15.3	+0.5	+0.7

Corporate actions

Upcoming

No upcoming corporate actions for RDY

Past

DividendQ3/26

Ex-dividend date24 Jul 2026

Payable dateN/A

Amount per share$0.08

Dr. Reddy`s Laboratories Ltd. - ADR (RDY) Stock

Fundamentals

Recent news

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

About Dr. Reddy`s Laboratories Ltd. - ADR

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

Corporate actions

Upcoming

Past

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade